Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study of ADXS-HPV (ADXS11-001) alone or in combination with MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The trial is expected to begin patient enrollment in early 2015.
{iframe}https://globenewswire.com/news-release/2014/12/15/691191/10112243/en/Advaxis-Announces-FDA-Acceptance-of-Its-Investigational-New-Drug-Application-to-Commence-Clinical-Trials-of-ADXS-HPV-in-Combination-With-MedImmune-s-MEDI4736-for-the-Treatment-of-H.html{/iframe}